To review, after 19 months on Lupron, Zytiga, prednisone, PSA increased on 1/23 to 0.253, then 0.309 on 2/21. Plarify scan showed only one active site in hip which was radiated. 4/4 PSA dropped to 0.24 which indicated the lesion was knocked out and I would be hormone sensitive and stay on Zytiga. Yea ! HOWEVER, 5/23 PSA went UP to 0.343. Now what? Am I now hormone resistant? Is Xtandi the next step ? Am I overreacting and should wait a couple of months for the next blood test. I would appreciate any thoughts from all of you.
5/25 update on Zytiga failed - Advanced Prostate...
5/25 update on Zytiga failed
Try switching to dexamethasone:
bjui-journals.onlinelibrary...
Since it worked for me, I obviously agree. This study came out in 2018... so, oh-informed-one, do you have any insight why this simple option seems to be routinely missed - or dismissed - by treatment specialists?
A friend just had it suggested by his oncologist last week. I don't know how prevalent it is. Some oncologists stay informed more than others.
My MO had me try that, but my PSA continued to rise. Next step is one of the ...lutemides.
I hope you mean enzalutamide and not bicalutamide.
Yea, enzalutemide, apalutemide or daralutemide.
Only enzalutamide is approved for mCRPC, although I've seen patients get the others from agreeable insurance companies.
I've heard that....will see. Nubequa seems to have less SE than the other two.
I'm not sure of that, also don't know which is most effective of those 3. NRG Oncology seems to prefer apalutamide. Enzalutamide has the longest history of use. Docetaxel seems to help it work longer.
Hi Sir, any thoughts on Abiraterone? My dad is currently taking Bicalutamide together with Leuprorelin. If Bicalutamide isn’t working anymore, dad needs to shift to either Xtandi or Zytiga according to urologist. Both are very expensive in my country and at the moment, dad couldn’t decide what options to take as sustainability of either is our optimum concern. Thank you